Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.The company’s lead candidate ivonescimab (SMT112) is an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.Akeso Inc. engineered Ivonescimab, which is currently in multiple Phase 3 clinical trials. Over 2,300 patients have been treate ...